Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis

Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S
Record ID 32011000723
English
Authors' objectives:

This study investigates the cost-effectiveness of Octaplas against standard FFP and its budgetary impact to the health care system. Specifically, the study answers the following research questions:
What is the cost-effectiveness of Octaplas versus standard frozen plasma (FP or FFP)?
What is the budget impact if Octaplas replaced a proportion of the FFP used in Canada (excluding Quebec), or if it replaced a proportion of the FFP cryosupernatant plasma (CSP) used in the treatment of thrombotic thrombocytopenic purpura in Canada?

Authors' recommendations: Octaplas is associated with only a minimal reduction in disease burden at a higher cost than standard FP or FFP. The high incremental cost per QALY results from low transfusion-related risks for FP or FFP engineered by advances in the safety measures of blood transfusion, such as testing, donor screening, and deferral. Switching to Octaplas may increase the volume of much needed IVIg and albumin. However, overall, in relative terms, the health care system incurs a net loss, as it could purchase the added volume of IVIg and albumin at lower total cost from its current suppliers.
Details
Project Status: Completed
URL for project: http://www.cadth.ca/media/pdf/Economic_Analysis_March%202011.pdf
Year Published: 2011
URL for published report: http://www.cadth.ca/en/products/health-technology-assessment/publication/806
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Humans
  • Plasma
  • Virus Diseases
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.